Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  London Stock Exchange  >  AstraZeneca    AZN   GB0009895292

Mes dernières consult.
Most popular
News SummaryMost relevantAll newsSector newsTweets

AstraZeneca plc : AstraZeneca and Bristol-Myers Squibb resubmit dapagliflozin New Drug Application for the treatment of type 2 diabetes in the U.S

share with twitter share with LinkedIn share with facebook
share via e-mail
07/25/2013 | 02:26pm CEST

AstraZeneca and Bristol-Myers Squibb today announced they have resubmitted to the U.S. Food and Drug Administration (FDA), a New Drug Application (NDA) for dapagliflozin for the treatment of adults with type 2 diabetes.

The NDA resubmission, which is pending acceptance by the FDA, includes several new studies and additional long-term data (up to four years' duration) from previously submitted studies.

NOTES TO EDITORS About dapagliflozin

Dapagliflozin, an investigational compound, is a selective and reversible inhibitor of sodium-glucose cotransporter 2 (SGLT2), which works independently of insulin. It is currently approved for the treatment of type 2 diabetes in the European Union, Australia, Brazil, Mexico and New Zealand.

About Type 2 Diabetes

In 2012, diabetes was estimated to affect more than 370 million people worldwide. The prevalence of diabetes is projected to reach more than 550 million by 2030. Type 2 diabetes accounts for approximately 90 to 95% of all cases of diagnosed diabetes in adults. Type 2 diabetes is a chronic disease characterised by insulin resistance and dysfunction of beta cells in the pancreas, leading to elevated glucose levels. Over time, this sustained hyperglycemia contributes to further progression of the disease. Significant unmet needs still exist, as many patients remain inadequately controlled on their current glucose-lowering regimen.

About AstraZeneca

AstraZeneca is a global, innovation-driven biopharmaceutical business that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of cardiovascular, metabolic, respiratory, inflammation, autoimmune, oncology, infection and neuroscience diseases. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide.www.astrazeneca.com

CONTACTS Media Enquiries

Esra Erkal-Paler +44 20 7604 8030 (UK/Global)
Vanessa Rhodes +44 20 7604 8037 (UK/Global)
Ayesha Bharmal +44 20 7604 8034 (UK/Global)
Michele Meixell +1 302 885 2677 (US)
Jacob Lund +46 8 553 260 20 (Sweden)

Colleen Proctor + 44 207 604 8128 mob: +1 302 357 4882
Ed Seage + 44 207 604 8125 mob: +1 302 373 1361

distributed by
share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on ASTRAZENECA
07/21 GlaxoSmithKline's new CEO prepares to trim drug pipeline
07/20 ASTRAZENECA : Patent Issued for Method and Device for Detection of Bioavailable ..
07/20 ASTRAZENECA : New Medicinal Chemistry Study Findings Recently Were Reported by R..
07/20 ASTRAZENECA : Kyntheum approved in the EU for the treatment of adults with moder..
07/16 ASTRAZENECA : Soriot not moving to Teva - Bloomberg
07/16 ASTRAZENECA : Maybe AstraZeneca Can Help?
07/14DJASTRAZENECA : CEO? We Still Don't Know If He's Staying or Going
07/14 ASTRAZENECA : offers no comment after report saying CEO staying
07/14 FTSE falters, narrowing weekly gain; Carillion sees small bounce
07/14 ASTRAZENECA : gets royal approval
More news
News from SeekingAlpha
07/21 Ironwood Will Press On In The Good Fight Against GERD
07/21 Tesaro's Stock Dip Is Nothing To Be Afraid Of
07/20 Looking For Value In The Deal Sweet Spot
07/20 AstraZeneca's Kyntheum OK'd in EU for plaque psoriasis
07/19 FDA's Flashing Green Light Boosts Novel Drug Approvals
Financials ($)
Sales 2017 21 464 M
EBIT 2017 5 969 M
Net income 2017 2 628 M
Debt 2017 12 461 M
Yield 2017 4,11%
P/E ratio 2017 30,92
P/E ratio 2018 24,72
EV / Sales 2017 4,51x
EV / Sales 2018 4,40x
Capitalization 84 409 M
Duration : Period :
AstraZeneca Technical Analysis Chart | AZN | GB0009895292 | 4-Traders
Technical analysis trends ASTRAZENECA
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 34
Average target price 67,8 $
Spread / Average Target 2,1%
EPS Revisions
Pascal Soriot Chief Executive Officer & Executive Director
Leif Valdemar Johansson Non-Executive Chairman
Pam P. Cheng Executive VP-Operations & Information Technology
Marc Dunoyer Chief Financial Officer & Executive Director
Sean Bohen Chief Medical Officer & Executive Vice President
Sector and Competitors
1st jan.Capitalization (M$)
ASTRAZENECA16.10%84 409
JOHNSON & JOHNSON17.45%367 897
NOVARTIS9.72%222 704
ROCHE HOLDING LTD.5.46%222 036
PFIZER3.08%199 735